Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The hypothesis of this study is that lenalidomide can be an effective drug in preventing
relapse of MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q
after allogeneic HSCT. Due to its immunomodulatory action it might also be able to enhance a
T - or NK cell mediated graft versus leukemia (GVL) effects. Nevertheless, one has to keep in
mind a possible, yet unknown influence on modulation of clinical GVHD.